What do you want to do today?
video_library
Watch On Demand
auto_awesome_motion
Discover Series
person_search
Search KOLs
campaign
Meet our Ambassadors
group_work
Meet Societies
handshake
Meet Partners
video_library
OnDemand
auto_awesome_motion
Series
person_search
Faculty
campaign
Ambassa-
dors
group_work
Societies
handshake
Partners

Only logged in users can watch the content

Chat keyboard_arrow_down
Description keyboard_arrow_down
Since the late 20th century, Chinese medicine has developed rapidly in comparison to the rest of the world, being China one of the countries which have made more significant advances in medical research and treatments. Aiming to provide a comprehensive, in-depth look at how Chinese medicine is practiced and examine its impact on global health, we are proud to introduce Meet the Masters, as part of the Healing in China series, which brings together the best Chinese KOLs and top surgeons from other regions of the world to guide you through their surgeries and transfer years of knowledge. In this event, AIS Channel specially invites top thoracic surgery experts from China, the United Kingdom and the United States to share academic insights on lobectomy after neoadjuvant therapy. This event features operation videos, case sharing, and interactive discussions to enhance surgical skills and improve global standards in this field.
Program

  1. Hospital/Department Introduction

  2. Welcome and Introduction – Dr. Di Ge (China)

  3. Case Introduction – Dr. Di Ge (China)

  4. Lobectomy After Neoadjuvant Therapy. Part 1 – Dr. Di Ge (China)

  1. Key Decision 1 Question – Dr. Alessandro Brunelli (UK) and Dr. Di Ge (China)

  1. Lobectomy After Neoadjuvant Therapy. Part 2 – Dr. Di Ge (China)

  1. Key Decision 2 Question – Dr. Douglas E. Wood (USA) and Dr. Di Ge (China)

  1. Lobectomy After Neoadjuvant Therapy. Part 3 – Dr. Di Ge (China)

  2. Key Decision 3 Question – Dr. Alessandro Brunelli (UK) and Dr. Di Ge (China)

  1. Lobectomy After Neoadjuvant Therapy. Part 4 – Dr. Di Ge (China)

  1. Key Decision 4 Question – Dr. Douglas E. Wood (USA) and Dr. Di Ge (China) 

  2. Panel Discussion - All faculty moderated by Dr. Di Ge (China)


Clinical case

Clinical history

  • Male, 65 years old

  • Found an occupying lesion in the right upper lobe 2 months ago 

  • History: NS

  • Physical Examination: (-)

  • Pulmonary function:

           -FEV1 :  2.04L, 

           -FEV1%: 81.34% of  predicted value

  • EKG: (-)

PET/CT  Scan

  • Aug 1st, 2022 
  • A peripheral lesion in the right upper lobe with a Max SUV value of 24.4, invading the adjacent mediastinal pleura, with possible metastasis to the lymph nodes station 4R.

Bronchoscopy + EBUS-TBNA（Lymph node station 4R)

  • Aug 3rd, 2022

  • Lymph node station 4R:  Squamous cell carcinoma (Low differentiation)

                -PD-L1 (28-8) (tumor -, 5% interstitial, TPS=0, CPS=5);  

                -PD-L1 (E1L3N) (tumor -, 5% interstitial, TPS=0, CPS=5)

Clinical Staging: cT3N2M0, IIIB - Preoperative Treatment (MDT)

  • Neoadjuvant Chemotherapy +ICIs based on III clinical studies Checkmate816

  • Treatment date: Aug 12th,  Sep 2th,  Sep 27th, 2022

  • Treatment plan: Albumin paclitaxel 440mg d1 + Carboplatin 435mg d1 + Nivolumab 200mg d1 q3w

  • Adverse reaction: Transient leukopenia occurred during the 2nd course of treatment, but was cured promptly was no delay in the subsequent treatment

Radiological outcome: Partial Response (PR)

Date of Operation: Oct 18th, 2022

  • VATS lobectomy of RUL
  • Wedge resection of RLL
  • Systemic dissection of mediastinal lymph node

Pathologic outcomes

  • No squamous cell carcinoma tissue
  • A small amount of adenocarcinoma tissue, acinar type, grade II, accounted for 5% of the tumor bed
  • Bronchial margin (-)
  • Lymph nodes (-)

Major Pathological Response (MPR),  Downstage

  • ypT1aN0M0
Faculty keyboard_arrow_down
Dr. Alessandro Brunelli MD, Consultant Thoracic Surgeon and Honorary Clinical Associate Professor, Department of Thoracic Surgery, St. James’s University Hospital, UK Cardiothoracic Surgery
Dr. Di Ge Professor, Chief Physician, Doctoral supervisor and Deputy Chief, Division of Thoracic Surgery; Director, Center of Lung Cancer; Chief, Section of Lung Surgery, Zhongshan Hospital, Shanghai Medical College Fu Dan University, China Cardiothoracic Surgery
Dr. Douglas E. Wood MD, FACS, FRCSEd, The Henry N. Harkins Professor and Chair of Surgery at the University of Washington, Thoracic surgeon, Cancer researcher, Advocate for lung cancer early detection, UW Medicine, USA Cardiothoracic Surgery
Hospital information keyboard_arrow_down

Shanghai Zhongshan Hospital Virtual COE Course



Department introduction
35 staff surgeons, divided into 6 groups with 129 beds. more than 9000 thoracic surgeries annually.
Faculties
Dr. Qun Wang M.D. FRCS
Chief Physician
Dr. Lijie Tan M.D. FACS
Chief Physician
Dr. Di Ge M.D. FCCP Chief Physician
Procedure trained
- Uniportal Vats Lobetomy
- Precise Location % Segmentoctomy for Pulmonary Nodules
Clinical Solution
- (Pre-OP) Patient indication, OR set up,
- (In-OP) Dissection technique of vessels, lobes resection. Avoiding complication
- (Post-OP) Managing complication
Technical Solution (safety use)
Harmonic 1000i, Powered Echelon flex+, (GST, PVS)
Learning Objectives
This course will help the participants to master the Uniportal Vats technique more proficiently
Target customer / Criteria
Fully Qualified physicians who already have experience in VATS and going to move to uniporta VATS.
Highlight for this course
Uniportal VATS
- Lobectomy Majority
- The World's First Book of Uniportal VATS
- Uniportal Video-assisted Thoracic Surgery by Dr. Lijie Tan

VATS Segmentectomy
- Hi-End VATS Segmentectomy
- Precise Location & Segmentectomy for Pulmonary Nodules
Yet, the VATS segmental surgery is increasing both in quantity and quality. We use pre-op 3D model to within the lung parenchyma.

Related Content keyboard_arrow_down